PARIS, July 21 Mauna Kea Technologies could
raise as much as 47.6 million euros ($67.73 million) from its
initial public offering, the proceeds of which it plans to use
to speed up sales of the world's smallest microscope that can be
used to examine the inside of the human body.
France's Mauna Kea said on Tuesday the price range of its
IPO on the NYSE Euronext stock exchange was set between 10.65
euros and 13 euros a share and that the offer would close on
Founded in 2000, France's MKT has made the world's smallest
microscope, Cellvizio, which stomach and lung specialists can
use to screen intestines or lungs for diseases like cancer.
MKT's IPO comes after Dutch company Agendia, which markets
breast cancer tests, pulled its bourse listing plans on Monday
evening because of volatile market conditions, showing that the
financing environment for biotech firms remains tough.
Also French construction materials maker Saint-Gobain
(SGOB.PA) decided to postpone the IPO its glass container unit